A Multicentre Trial to Evaluate the Efficacy and Tolerability of α-Glycerylphosphorylcholine versus Cytosine Diphosphocholine in Patients with Vascular Dementia

  title={A Multicentre Trial to Evaluate the Efficacy and Tolerability of $\alpha$-Glycerylphosphorylcholine versus Cytosine Diphosphocholine in Patients with Vascular Dementia},
  author={Raoul Di Perri and Giovanni Coppola and L A Ambrosio and Antonino Grasso and F. M. Puca and Mimma Rizzo},
  journal={Journal of International Medical Research},
  pages={330 - 341}
An open clinical trial was carried out to compare the efficacy and the tolerability of 1 g/day α-glycerylphosphorylcholine (α-GPC) with 1 g/day cytosine diphosphocholine (CDP) both given intramuscularly for 90 days in 120 patients with mild to moderate vascular dementia. The clinical evaluation, carried out at the start as well as halfway through (45 days) and at the end of treatment (90 days), was expressed by psychometric tests (modified Parkside behaviour rating scale, Sandoz clinical… 

Figures and Tables from this paper

Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial
The combined choline alphoscerate–nimodipine treatment showed no significant effect in the cohort of VCI patients with SVD and the safety profile was good overall.
Multicentre Study of l-α-Glyceryl-Phosphorylcholine vs ST200 among Patients with Probable Senile Dementia of Alzheimer’s Type
Positive findings require replication in larger, double-blind, longitudinal studies coupling clinical and biological determinations, and significant improvements in most neuropsychological parameters in the αGPC recipients.
α‐Glycerophosphocholine in the Mental Recovery of Cerebral Ischemic Attacks
The clinical efficacy and the tolerability of alpha-glycerophosphocholine (alpha-GPC), a drug able to provide high levels of choline for the nervous cells of the brain and to protect their cell
Long-Term Citicoline (Cytidine Diphosphate Choline) Use in Patients with Vascular Dementia: Neuroimaging and Neuropsychological Outcomes
The efficacy of long-term citicoline treatment for cognitive impairment and neuropathological decline in those patients already meeting criteria for VaD does not appear to be substantiated by the current study.
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial—the CONIVaD trial
The CONIVaD study is the first randomized controlled trial to examine the cognitive efficacy of combined choline alphoscerate–nimodipine treatment in VCI patients, and will serve as a methodological basis for other clinical controlled, multicentric, double-blinded, and randomized trials.
Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data
Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
There was some evidence that CDP-choline has a positive effect on memory and behaviour in at least the short to medium term, but the evidence of benefit from global impression was stronger, but is limited by the duration of the studies.
Positive results should be regarded with caution due to the small number of patients included in controlled clinical trials using cholinergic precursors and to the limited number and sample size of trials with AChE and ChE inhibitors, but among compounds investigated, choline alphoscerate was well tolerated, improved cognitive function in VaD patients to a better extent than citicoline and to similar orbetter extent than other more recently developed drugs.


Pharmacological approaches in the treatment of senile dementia.
Preliminary results of a 2-month study indicate that CBM 36-733 has beneficial effects in patients with mild to moderate degrees of degenerative dementia and it will be of interest to clinically evaluate in long-term studies the potential of this drug to slow down the progression of neurodegenerative processes.
[Evaluation of the effects of citicoline in chronic cerebrovascular diseases].
Citicoline treatment brought about an improvement in awareness and perceptive-motor faculties and can be attributed to an overall drug action on neural energy metabolism.
The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease.
A double-blind crossover trial is described in which the effect of cyclandelate is assessed on patients admitted to a psychiatric hospital who were severely handicapped with symptoms due to arteriosclerotic brain disease, suggesting that enhancing the cerebral circulation produces a favourable clinical response.
A New Scale for Clinical Assessment in Geriatric Populations: Sandoz Clinical Assessment – Geriatric (SCAG) *
The statistical findings indicated that SCAG is a valid and reliable instrument for assessing psychopathology in the elderly.
Senile dementia of the Binswanger type. A vascular form of dementia in the elderly.
The name senile dementia of the Binswanger type (SDBT) is proposed for this poorly recognized, vascular form of subcortical dementia that probably results from cortical disconnection most likely caused by hypoperfusion and may be a potentially preventable and treatable form of dementia.
Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups.
The data underline the difficulties in drawing clear demarcation lines between normal and pathological aging and between different subgroups of dementia.
Cerebral blood flow in dementia.
Cerebral blood flow per 100 gm brain per minute was normal in the primary degenerative group but low in the multi-infarct group, suggesting the blood flow is adequate for metabolic needs of the brain in patients withPrimary degenerative dementia but inadequate for those with multi- infarct dementia.
The decline and resurgence of vascular dementia.
  • V. Hachinski
  • Medicine, Psychology
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 1990
Growing evidence suggests that not only grey matter lesions but also white matter lesions contribute to dementia, that vascular factors commonly coexist and interact with Alzheimer changes and that Alzheimer's disease has a vascular and potentially treatable component.
The decline and resurgence of vascular dementia
Growing evidence suggests that not only grey matter lesions but also white matter lesions contribute to dementia, that vascular factors commonly coexist and interact with Alzheimer changes and that Alzheimer9s disease has a vascular and potentially treatable component.